Japan has approved Alexion’s Soliris® (eculizumab) as a treatment for patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy or plasmapheresis.

“This approval is great news for patients with gMG in Japan who fail to adequately respond to existing therapies and continue to face significant disease symptoms,” said Michiyo Sakurai, President of the Japanese Myasthenia Gravis Association, Kyoto, Japan.

press release
article in Hartford Business.com